Excelsior Biopharma Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 186.53 million compared to TWD 175.52 million a year ago. Net loss was TWD 37.17 million compared to TWD 10.05 million a year ago. Basic loss per share from continuing operations was TWD 0.81 compared to TWD 0.22 a year ago. Diluted loss per share from continuing operations was TWD 0.81 compared to TWD 0.22 a year ago.
For the nine months, sales was TWD 562.39 million compared to TWD 504.49 million a year ago. Net loss was TWD 97.26 million compared to TWD 32.62 million a year ago. Basic loss per share from continuing operations was TWD 2.12 compared to TWD 0.71 a year ago. Diluted loss per share from continuing operations was TWD 2.12 compared to TWD 0.71 a year ago.